CHECK WITH YOUR PERSONAL PHARMACIST WE ARE HERE TO HELP.
New Vaccinations for RSV
CHECK WITH YOUR PERSONAL PHARMACIST WE ARE HERE TO HELP.
When do you call your Personal Pharmacist?
When you or your client has any questions you’d like answered by a pharmacist.
We are medication experts and are here to help you. Pharmacist: 814-297-9960
New Vaccinations for RSV Current recommendations could impact adults 60 years of age and older and infants |
What Are These Vaccines?
The first two approved vaccines approved for preventing symptomatic RSV lower respiratory tract disease are, Arexvy (GSK) and Abrysvo (Pfizer). They are both approved for adults 60 year of age and older as a single-dose vaccination to prevent the morbidity associated with RSV in this population.
Arexvy (GSK), approved May 2023 | Abrysvo (Pfizer), approved May 2023, FDA-approved for pregnant women August 2023 |
Important update: As of September 22, 2023, “the CDC recommends the RSV vaccine during 32-36 weeks of pregnancy to help protect babies from severe RSV.”
The estimated cost of these vaccines are around Direct costs associated with hospitalisation from |
RSV is a relatively common virus that usually Reducing risk of complications of RSV in these two populations can save the health plan in the costs Please note: It is important to recognize the signs |
|
|
|
|
|
Monoclonal Antibodies for RSV Meant to protect children from severe RSV |
What Are These Monoclonal Antibodies?
Nirsevimab (Beyfortus) and palivizumab (Synagis)he are two monoclonal antibody products approved for use in babies and children to protect against severe disease from an RSV infection. These are NOT VACCINES. While they do provide protection against infection, their efficacy is not long-standing and it is not recommended to give if a child already has an RSV infection. While individual treatment may be subject to variation and provider guidance, the following has been recommended by the CDC:
|
|
What is the projected cost?
The mean cost for one RSV-related hospitalization was estimated to be of $8,910 by the National Institutes of Health.
|
|
RSV is a relatively common virus that usually presents with mild cold-like symptoms. Statistically, most children are already exposed to RSV by the age of two. In young children and infants, it can be difficult to breathe with RSV, and there is concern around this. RSV is serious, causing childhood respiratory illness, hospitalization, and in some cases death. The CDC has issued recommendations for all children to have access to these preventative therapies.
|
|
|
814.297.9960 • help@personalpharmacist.com • www.personalpharmacist.com